Topiramate (Epilepsy)

Cognitive developmental disorders/delay (> 6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15875
R65449		 Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 Intellectual disability - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 2.71 [1.05;6.98] C
excluded (control group) 		5/290   34/5,288 39 290
ref
S15876
R65458		 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Intellectual disability - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: Yes 2.23 [0.90;5.50] 5/290   184/22,203 189 290
ref
S7307
R53763		 Bromley (Topiramate), 2016 Full-scale IQ <85 (Wechsler Preschool and Primary Scale of Intelligence (WPPSI) / Wechsler Intelligence Scale for Children (WISC)) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No 2.17 [0.41;11.53] C 3/27   3/55 6 27
ref
Total 2 studies 2.22 [1.00;4.91] 195 317
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023Dreier, 2023 1 2.23[0.90; 5.50]18929077%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Bromley (Topiramate), 2016Bromley, 2016 2 2.17[0.41; 11.53]62723%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 2.22[1.00; 4.91]1953170.95.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Epilepsy) (Controls unexposed, sick; 2: Topiramate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.22[1.00; 4.91]1953170%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 2.22[1.00; 4.91]1953170%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 Tags Adjustment   - No  - No 2.17[0.41; 11.53]627 -NABromley (Topiramate), 2016 1   - Yes  - Yes 2.23[0.90; 5.51]189290 -NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 1 All studiesAll studies 2.22[1.00; 4.91]1953170%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 15875

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 2.22[1.00; 4.91]1953170%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.71[1.05; 6.98]39290 -NADreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 10.510.01.0